Sprint Bioscience AB (SPRINT) AI Stock Analysis

• Market Cap: kr171.46M
• Dividend Yield: N/A
• Average Volume (3M): 560.98K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.33
• Revenue Growth: -17.80%
• EPS Growth: -11.96%
• Country: SE
• Employees: 38
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.08
• Shares Outstanding: 105,515,540
• 10 Day Avg. Volume: 1,502,692
• 30 Day Avg. Volume: 560,983
• PEG Ratio: >-0.01
• Price to Book (P/B): 11.75
• Price to Sales (P/S): 1.66
• P/FCF Ratio: -4.42
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: kr1.50 ▲(1.35% Upside)

The score is held back primarily by weak financial performance—declining TTM revenue, large losses, shrinking equity, and significant negative free cash flow—despite the benefit of zero debt. Technicals are a relative positive (price above longer-term moving averages and positive MACD), but valuation remains challenged due to ongoing losses and no dividend yield data.

Positive Factors

Zero reported debt

Having no reported debt materially lowers fixed financial obligations and reduces bankruptcy and interest-rate risk. For a small biotech, zero leverage preserves strategic flexibility to time equity raises, partner deals or milestone-driven financing without servicing debt that could constrain R&D investment.

Partnering/licensing business model

A licensing-and-partnering model aligns costs and risks with larger pharmaceutical partners, enabling Sprint to focus on early discovery while shifting expensive clinical development. This model is capital-efficient long term and creates scalable upside via upfronts, milestones and royalties without sustaining large in-house late-stage budgets.

Prior positive cash flow year

Achieving positive operating and free cash flow in 2023 demonstrates the business can reach breakeven under the right revenue mix or timing of partner payments. This shows the operating model can become self-funding episodically, supporting sustainability if partnership cadence and milestone timing improve.

Negative Factors

TTM revenue decline

A sustained 16% drop in TTM revenue signals weakening commercial traction or fewer partner transactions, directly reducing near-term upfronts and milestone income. For a partner-dependent biotech, falling revenue undermines cash runway, bargaining leverage in deals and the company’s ability to fund discovery programs without external financing.

Substantial cash burn

Large negative operating and free cash flows over the trailing twelve months indicate the company is consuming cash faster than it generates it, creating persistent financing need. This increases dilution risk, may force asset sales or hurried licensing terms, and constrains long-term program investment unless partner cadence improves.

Eroding equity and big losses

Steep equity erosion and a ~25.6M net loss in TTM reflect accumulated value destruction, reducing balance-sheet resilience. Shrinking equity limits ability to absorb shocks, undermines investor confidence and increases reliance on dilutive financing or strategic exits, which can impair long-term investment in discovery programs.

Sprint Bioscience AB Business Overview & Revenue Model

Company Description

Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.

How the Company Makes Money

Sprint Bioscience generates revenue primarily through collaboration and licensing agreements with larger pharmaceutical companies. By advancing its drug candidates to a preclinical stage, the company positions itself to enter partnerships where it grants rights to its drug candidates in exchange for upfront payments, milestone payments, and royalties on future sales. These partnerships allow Sprint Bioscience to leverage the resources and expertise of established pharma companies to bring its innovations to market. Additionally, the company may receive government grants or research funding to support its development projects, although these are not its primary revenue streams.

Sprint Bioscience AB Financial Statement Overview

Summary

Financials are pressured by ~16% TTM revenue decline, materially negative profitability (net loss ~25.6M; ~-52% net margin), and significant cash burn (TTM operating cash flow ~-37.7M; free cash flow ~-38.3M). A key positive is zero reported debt, but equity has shrunk sharply (about 27.8M in 2023 to ~6.1M in TTM), indicating ongoing value erosion.

Income Statement

TTM (Trailing-Twelve-Months) revenue declined ~16% versus the prior period, and profitability remains weak with a net loss of ~25.6M and a net margin around -52%. Gross margin also compressed to ~38% in TTM versus ~57% in 2024, pointing to weaker economics or a less favorable revenue mix. While 2023 showed near break-even results after a sharp rebound from 2022, the company has since reverted to sizable operating losses, indicating limited earnings stability.

Balance Sheet

Leverage is a clear strength: total debt is reported at 0 in recent periods (TTM and 2021–2024), which reduces financial risk. However, the balance sheet has weakened as losses accumulated—equity fell sharply (about 27.8M in 2023 to ~9.3M in 2024 and ~6.1M in TTM), and returns on equity are deeply negative in TTM, reflecting ongoing value erosion for shareholders.

Cash Flow

Cash generation is a key concern: TTM (Trailing-Twelve-Months) operating cash flow is about -37.7M and free cash flow about -38.3M, indicating meaningful cash burn. Although free cash flow improved versus the prior period (positive growth rate), it remains firmly negative and not self-funding. The company did generate positive operating and free cash flow in 2023, but the reversion to sizable outflows in 2024 and TTM highlights volatility and financing dependence.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	49.53M	65.64M	50.48M	83.00K	35.11M	16.89M
Gross Profit	18.82M	37.30M	41.79M	-60.91M	24.68M	6.43M
EBITDA	-23.34M	-17.32M	396.00K	-60.00M	-24.49M	-38.05M
Net Income	-25.65M	-18.28M	-438.00K	-60.17M	-25.35M	-46.23M
Balance Sheet
Total Assets	21.44M	42.05M	62.38M	37.42M	79.14M	33.40M
Cash, Cash Equivalents and Short-Term Investments	10.95M	25.06M	49.93M	29.49M	70.64M	27.07M
Total Debt	0.00	0.00	0.00	0.00	0.00	10.00M
Total Liabilities	15.37M	32.78M	34.60M	9.23M	8.68M	24.25M
Stockholders Equity	6.06M	9.27M	27.77M	28.19M	70.45M	9.14M
Cash Flow
Free Cash Flow	-38.28M	-24.65M	20.42M	-59.05M	-42.82M	-32.22M
Operating Cash Flow	-37.71M	-23.36M	22.87M	-59.05M	-40.12M	-32.22M
Investing Cash Flow	-570.00K	-1.30M	-2.45M	0.00	-2.71M	0.00
Financing Cash Flow	18.23M	-225.00K	24.00K	17.90M	86.39M	50.92M

Sprint Bioscience AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.48
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SPRINT, the sentiment is Positive. The current price of 1.48 is below the 20-day moving average (MA) of 1.55, above the 50-day MA of 1.45, and above the 200-day MA of 0.79, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 68.23 is Neutral, neither overbought nor oversold. The STOCH value of 79.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SPRINT.

Sprint Bioscience AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2CUREX	54 Neutral	kr55.48M	-10.28	-304.59%	11.26%	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SPRINT	49 Neutral	kr171.46M	-5.39	-264.12%	―	-17.80%	-11.96%
EXPRS2	46 Neutral	kr51.97M	-0.79	-88.65%	―	8.46%	11.73%
CMOTEC.B	45 Neutral	kr92.44M	-11.78	-114.00%	―	132.07%	54.65%
LIDDS	43 Neutral	kr2.43M	-0.51	-132.58%	―	―	86.26%
LARK	43 Neutral	kr43.76M	-0.98	―	8.47%	-94.12%	-25.83%